Table 4.
Treatment-related features
| Reference | Radiotherapy | Induction chemotherapy | Concurrent chemotherapy | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | Regimena | Dose (Gy) | Number of patients | Type of chemotherapy | No. of cycles (median) | Number of patients | Type of chemotherapy | No. of cycles (median) | |||
| 3DCRT | IMRT | Total (median) | Per fraction | ||||||||
| [18] | 32 | 30 | Conventional | 70 | 2 | 20 | Docetaxel/cisplatin | ns | 35 | Cisplatin 40 mg/m2 every 7 days | 6 |
| [19] | 0 | 26 | Conventional | 70 | 1.8 | 0 | Not administered | 0 | 26 | Cetuximab | ns |
| [20] | 0 | 122 | Conventional | 70 | 2 | 0 | Not administered | 0 | 122 | Cisplatin 100 mg/m2 every 21 days | ns |
| [21] | 0 | 51 | Conventional | 70 | ns | 0 | Not administered | 0 | 51 | Cisplatin 100 mg/m2 every 21 days | ns |
| [22] | ns | ns | Conventional | 72 | 2 | 0 | Not administered | 0 | 44 | Cisplatin 100 mg/m2 every 21 days | ns |
| [23] | ns | ns | Conventional | 72 | 2 | 0 | Not administered | 0 | 68 | Cisplatin 100 mg/m2 every 21 days | ns |
| [24] | 0 | 88 | Conventional | 70 | 2 | 0 | Not administered | 0 | 74 | Cisplatin + 5-fluorouracil | ns |
| [25] | 0 | 70 | Conventional | 66 | 1.8 | 0 | Not administered | 0 | 70 | Cisplatin 100 mg/m2 every 21 days | ns |
| [26] | ns | ns | Conventional | 70 | 2 | 0 | Not administered | 0 | 70 | Other | ns |
| [27] | 0 | 108 | Conventional | 70 | 2 | 48 | Docetaxel/cisplatin | 2 | 44 | Cisplatin + 5-fluorouracil | 6 |
| [28] | 0 | 75 | Conventional | 70 | 2 | 0 | TPF | 1 | 75 | Cisplatin 100 mg/m2 every 21 days | ns |
| [29] | ns | ns | ns | ns | ns | 0 | Not administered | ns | ns | ns | ns |
| [30] | 40 | 0 | Conventional | 70 | 2 | 0 | Not administered | 0 | 35 | Cisplatin 30 mg/m2 every 7 days | ns |
| [31] | 0 | 69 | Conventional | 70 | 2 | 15 | ns | ns | 46 | Cisplatin 40 mg/m2 every 7 days | ns |
| [32] | 0 | 72 | Conventional | 70 | 2 | 15 | ns | ns | 40 | Cisplatin 30 mg/m2 every 7 days | 6 |
| [34] | ns | ns | Conventional | 66 | 2 | 0 | Not administered | 0 | 85 | Other | 6 |
| [35] | 5 | 42 | Conventional | 66 | 2 | 0 | Not administered | 0 | 47 | Cisplatin + 5-fluorouracil | ns |
| [36] | 0 | 86 | Conventional | 72 | 2 | 0 | Not administered | 0 | 86 | Other | ns |
| [37] | ns | ns | Conventional | 70 | 2 | 0 | Not administered | 0 | 47 | Cisplatin + 5-fluorouracil | ns |
| [38] | 0 | 287 | Conventional | 66 | 2 | 26 | ns | ns | 86 | Other | ns |
| [39] | 0 | 100 | Accelerated | 69.96 | 2.12 | 0 | Not administered | 0 | 100 | Cisplatin 100 mg/m2 every 21 days | ns |
| [40] | ns | ns | ns | ns | ns | 0 | Not administered | 0 | 74 | Cisplatin 100 mg/m2 every 21 days | ns |
| [42] | 0 | 125 | Conventional | 70 | 2 | 0 | Not administered | 0 | 125 | Cisplatin 100 mg/m2 every 21 days | ns |
| [43] | 0 | 40 | Conventional | 70.2 | 1.8 | 40 | Docetaxel/cisplatin | 3 | 36 | Cisplatin 100 mg/m2 every 21 days | ns |
| [44] | 0 | 76 | Conventional | 72 | 2 | 0 | Not administered | 0 | 76 | Cisplatin 100 mg/m2 every 21 days | ns |
ns not stated, 3DCRT 3-D conformal radiotherapy, IMRT intensity-modulated radiotherapy, TPF docetaxel, cisplatin, 5-fluorouracil
aConventional: conventional once-daily fractionation. Accelerated: accelerated fractionation